POSIFIT
Richard Zimmermann is a seasoned professional in the field of nuclear medicine, holding the position of Senior Consultant at Chrysalium Consulting SARL since July 2012, where Richard focuses on business development and translational processes related to radiopharmaceuticals and particle therapy. Richard is also the Founder and President of the Oncidium Foundation, dedicated to promoting nuclear medicine therapies, and currently serves as President of POSIFIT, aiming to transform it into a prominent French CDMO for radiotheranostics. Co-founding MEDraysintell in 2013, Richard has contributed to strategic intelligence in the medical radiation sector. Richard's previous roles include General Manager at Global Morpho Pharma SAS, President of ANMI, and various leadership positions at IBA and Schering AG, showcasing extensive expertise and a strong academic background in organic chemistry and molecular pharmacology.
This person is not in the org chart
This person is not in any teams
POSIFIT
POSIFIT S.A.S. is a private company created in 2007. It participates in NANCYCLOTEP G.I.E., as one of its founding members, particularly in charge of pharmaceutical valorisation. Its expertise focuses on in vivo diagnostics : -Transfer of new radiopharmaceuticals to comply with GMP regulatory, -Production and quality control of radiopharmaceuticals.